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Abstract. 
 
Myogenesis is regulated by cell adhesion re-
 
ceptors, including integrins of the 
 
b
 
1 family. We report 
the identiﬁcation of a novel muscle-speciﬁc 
 
b
 
1 integrin 
binding protein (MIBP). MIBP binds to the membrane-
proximal cytoplasmic region shared by 
 
b
 
1A and 
 
b
 
1D 
integrins, and the binding occurs in vivo as well as in 
vitro. Furthermore, we show that MIBP is abundantly 
expressed by C2C12 myogenic cells before fusion, and 
the expression of MIBP is dramatically downregulated 
during subsequent differentiation. Finally, we show that 
overexpression of MIBP in C2C12 cells resulted in a 
suppression of fusion and terminal differentiation, sug-
gesting that MIBP may play a key role in controlling 
the progression of muscle differentiation.
Key words: integrin binding protein • muscle • myo-
genic differentiation • signal transduction • myogenin
 
T
 
HE
 
 formation of muscle fibers from individual myo-
blasts is a highly orchestrated process that is regu-
lated in part by interactions of cell adhesion macro-
molecules (McDonald et al., 1995; Sastry and Horwitz,
 
1996). Integrins of the 
 
b
 
1 family are cell adhesion recep-
tors that have been implicated in a wide variety of devel-
opmental processes (Brakebusch et al., 1997). At present,
12 
 
a
 
 subunits are known, of which 9 (
 
a
 
1, 
 
a
 
2, 
 
a
 
4, 
 
a
 
5, 
 
a
 
6, 
 
a
 
7,
 
a
 
9, 
 
a
 
11, and 
 
a
 
V) are expressed by skeletal muscle either
during differentiation or by mature muscle cells (Gullberg
et al., 1998). Several results suggest that integrins of the 
 
b
 
1
family play key regulatory roles in muscle development.
For example, overexpression of the 
 
a
 
5 subunit in quail
myoblasts results in continued cell proliferation, whereas
overexpression of the 
 
a
 
6 subunit promotes muscle differ-
entiation (Sastry et al., 1996). Other studies using chimeric
transgenic mice that were 
 
a
 
5 integrin
 
2
 
/
 
2
 
;
 
1
 
/
 
1
 
 showed
that the 
 
a
 
5
 
2
 
/
 
2
 
 cells were able to contribute to skeletal
muscle, but the myofibers were unstable, resulting in a
form of muscular dystrophy (Taverna et al., 1998). Similar
results showing a mild muscular dystrophy were obtained
with a targeted deletion of the 
 
a
 
7 integrin chain (Mayer et
al., 1997), and mutations in the human integrin 
 
a
 
7 gene
lead to a congenital myopathy (Hayashi et al., 1998). Dif-
ferential splicing of primary transcripts may also be impor-
tant for the progression of myogenesis, both for the 
 
a
 
7
chain (Burkin and Kaufman, 1999) and for the 
 
b
 
1 chain,
which switches during myogenesis from the 
 
b
 
1A isoform
to the 
 
b
 
1D isoform (de Melker and Sonnenberg, 1999).
Other studies using 
 
b
 
1
 
2
 
/
 
2
 
 cells obtained from transgenic
mice clearly show that the 
 
b
 
1 subunit is not essential for
muscle differentiation (Hirsch et al., 1998), although simi-
lar experiments with 
 
b
 
1
 
2
 
/
 
2
 
 cells in cardiac muscle show
delayed differentiation (Fässler et al., 1996). The 
 
b
 
1 inte-
grins, although only one of several receptor families
mediating cell adhesion in muscle development, neverthe-
less are likely to play important regulatory roles in the
process.
Considerable progress was made recently by Sastry et al.
(1999), who demonstrated that the 
 
b
 
1 integrin cytoplasmic
domain directly influences myoblast proliferation and dif-
ferentiation. Since the 
 
b
 
1 integrin cytoplasmic domain
lacks catalytic activity, this implies a critical role for poten-
tial 
 
b
 
1 integrin cytoplasmic binding partners in the regula-
tion of myogenic differentiation. Using yeast two-hybrid
methodology, we report the identification of a novel mus-
 
cle integrin binding protein (MIBP)
 
1
 
 that binds to the
 
Address correspondence to Chuanyue Wu, VH 217, Department of Cell
Biology, University of Alabama at Birmingham, 1670 University Blvd.,
 
Birmingham, AL 35294-0019. Tel.: (205) 975-2253. Fax: (205) 934-7029.
E-mail: cwu@cellbio.bhs.uab.edu
 
1. 
 
Abbreviations used in this paper:
 
 GST, glutathione 
 
S
 
-transferase; MBP,
maltose binding protein; MIBP, muscle integrin binding protein.
 
Brief Report 
The Journal of Cell Biology, Volume 147, 1999 1392
 
membrane-proximal cytoplasmic region shared by 
 
b
 
1A
and 
 
b
 
1D. Furthermore, MIBP expression was dramati-
cally downregulated during C2C12 myogenic differentia-
tion, and overexpression of MIBP in myogenic cells re-
sulted in a suppression of myogenesis. The results suggest
that MIBP may play an important role in controlling mus-
cle differentiation.
 
Materials and Methods
 
Cells, Antibodies, and Other Reagents
 
Mouse myoblast cells C2C12 and African green monkey COS-7 cells were
from American Type Culture Collection. Cells were maintained in DME
supplemented with 10% FBS, 100 U/ml penicillin, and 100 
 
m
 
g/ml strepto-
mycin. Rabbit anti–
 
b
 
1 integrin antibody MC231 was kindly provided by
Dr. John A. McDonald (Mayo Clinic, Scottsdale, AZ). Mouse mono-
clonal antimyogenin F5D was obtained from the Developmental Studies
Hybridoma Bank.
 
Yeast Two-Hybrid Assays
 
A cDNA fragment encoding the cytoplasmic domain of human integrin
 
b
 
1D (residues 749–801) was amplified by PCR and inserted into the
EcoRI/XhoI site in the pLexA vector (pLexA/
 
b
 
1D). The bait construct
was introduced into EGY48 (p8op-lacZ) yeast cells by transformation.
The transformants were used to screen a human heart MATCHMAKER
LexA cDNA library (
 
.
 
3 
 
3 
 
10
 
6
 
 independent clones) as described previ-
ously (Tu et al., 1999). To analyze protein–protein interaction between
MIBP and 
 
b
 
1 mutants, yeast cells were cotransformed with pB42AD and
pLexA expression vectors encoding MIBP and the 
 
b
 
1 sequences. The
transformants were plated and growth of blue colonies in the 
 
leucine
 
-defi-
cient medium indicates a positive interaction (Tu et al., 1999).
 
Northern Blot
 
A MIBP cDNA probe was prepared by labeling the full-length human
MIBP cDNA using an AlkPhos-direct labeling-detection system (Amer-
sham Pharmacia Biotech). A blot containing equal amounts of polyA
 
1
 
RNA (2 
 
m
 
g/lane) from different human tissues (Clontech Laboratories,
Inc.) was hybridized with the MIBP probe. The hybridized mRNA bands
were detected with CDP-
 
Star
 
 Detection System (Amersham Pharmacia
Biotech).
 
Immunoblotting of Human Tissues for MIBP
 
Human fetal tissues were washed twice with PBS, homogenized in lysis
buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA, 0.2 mM 4-(2-aminoethyl)ben-
zenesulfonylfluoride, HCl, 10 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml pepstatin A, and 5
 
m
 
g/ml leupeptin), and analyzed by immunoblotting with monoclonal anti-
MIBP antibody 5B4.7.
 
Expression and Purification of Recombinant Maltose 
Binding Protein, Glutathione S-transferase–, and
His-tagged Fusion Proteins
 
DNA constructs encoding maltose binding protein (MBP)–MIBP
(pMAL-c2/MIBP), glutathione 
 
S
 
-transferase (GST)–
 
b
 
1D (pGEX-5x-1/
 
b
 
1D), and His–MIBP (pET-15b/MIBP) fusion proteins were generated by
inserting cDNAs encoding full-length or partial sequences of human
MIBP and 
 
b
 
1D integrin into the corresponding vectors. The recombi-
nant vectors were used to transform 
 
Escherichia coli
 
 cells, and the re-
combinant proteins were purified with glutathione–Sepharose 4B beads,
amylose-agarose beads, and His-Bind
 
R
 
 Resin (Novagen), respectively.
 
Production and Characterization of a Monoclonal
Anti-MIBP Antibody
 
Mouse monoclonal anti-MIBP antibody was generated using purified
His–MIBP recombinant protein as an antigen (Tu et al., 1999). Hybrid-
oma supernatants were screened for anti-MIBP antibody activity by
 
ELISA and immunoblotting. One mAb (clone 5B4.7) recognized MBP–
MIBP and His–MIBP but not MBP or irrelevant His-tagged proteins.
 
Coprecipitation Assays
 
For direct binding assays, glutathione–Sepharose 4B beads were preincu-
bated with affinity-purified GST fusion protein containing the 
 
b
 
1D cyto-
plasmic domain (GST–
 
b
 
1D) or GST as a control (5 
 
m
 
g/30 
 
m
 
l beads), and
then mixed with His–MIBP (5 
 
m
 
g) and incubated at 4
 
8
 
C for 1 h. After
washing, His–MIBP coprecipitated with GST–
 
b
 
1D was detected by im-
munoblotting with anti-MIBP antibody 5B4.7. To perform GST fusion
protein pull down assays using cell lysates, C2C12 cells were washed once
with cold PBS and lysed with the lysis buffer (PBS, 1% Triton X-100,
0.2 mM 4-(2-aminoethyl)benzenesulfonylfluoride, HCl, 10 
 
m
 
g/ml aproti-
nin, 1 
 
m
 
g/ml pepstatin A and 5 
 
m
 
g/ml leupeptin). The cell lysates (500 
 
m
 
g)
were incubated with equal amounts (10 
 
m
 
g) of GST–
 
b
 
1D, or GST alone as a
negative control, and the GST fusion proteins were precipitated with glu-
tathione–Sepharose 4B beads. MIBP in the precipitates was detected by
immunoblotting with anti-MIBP antibody 5B4.7.
 
Coimmunoprecipitation Assays
 
The full-length MIBP cDNA was inserted into the HindIII/SalI site of
pFLAG-CMV2 vector (Kodak). COS-7 cells were transfected with
pFLAG-MIBP, or pFLAG-CMV2 as a control, using Lipofectamine Plus
(Life Technologies, Inc.). 48 h after transfection, the cells were lysed using
lysis buffer. Cell lysates (500 
 
m
 
g protein) were incubated with agarose
beads conjugated with mouse monoclonal anti-FLAG antibody M2 (50 
 
m
 
l)
or protein A–agarose beads coupled with an irrelevant mouse IgG (50 
 
m
 
l)
at 4
 
8
 
C for 1 h. The beads were washed and FLAG-MIBP and 
 
b
 
1 integrin
were detected in precipitates by immunoblotting with anti-FLAG anti-
body M5 and anti–
 
b
 
1 integrin antibody MC231, respectively.
 
Myogenic Differentiation
 
C2C12 cells were cotransfected with pFLAG-MIBP (or FLAG-CMV2 as
a control) and a vector containing a neomycin-resistant marker pEGFP-
c2; Clontech Laboratories Inc., using Lipofectamine Plus. The transfec-
tants were selected with 0.5 mg/ml G418 and cloned. Five clones (E3.11,
D9.8, B3, C4, and D4) that stably express FLAG-MIBP were obtained.
The expression of FLAG-MIBP by the transfectants was analyzed by im-
munofluorescence staining and immunoblotting with anti-FLAG antibody
M5. To analyze the effect of MIBP overexpression on myogenic differen-
tiation, C2C12 cells stably expressing FLAG-MIBP, FLAG control trans-
fectants, and the parental C2C12 cells were grown in DME containing
10% FBS in 24-well collagen-coated plates (Becton Dickinson) until con-
fluence was reached. Myogenic differentiation was induced by switching
the medium to DME containing 2% horse serum. Myogenin was detected
by immunoblotting with monoclonal antimyogenin antibody F5D.
 
Results
 
Identification and Cloning of a Novel MIBP
 
We have used yeast two-hybrid screens to identify 
 
b
 
1 in-
tegrin cytoplasmic binding proteins. A bait construct
(pLexA/
 
b
 
1D) encoding the 
 
b
 
1D integrin cytoplasmic do-
main (residues 749–801) was used to screen a human heart
LexA cDNA library (
 
.
 
3 
 
3
 
 10
 
6
 
 independent clones). 15
positive clones were obtained. DNA sequencing showed
that plasmids from 3 out of the 15 positive clones con-
tained an open reading frame encoding a novel protein
that we termed muscle integrin binding protein or MIBP
(Fig. 1 A). The binding of MIBP to the 
 
b
 
1D cytoplasmic
domain was confirmed by yeast two-hybrid binding assays
using purified pB42AD encoding MIBP (Table I). In con-
trol experiments, elimination of either the 
 
b
 
1D or MIBP
sequence failed to activate the reporter genes. In addition,
replacement of the integrin cytoplasmic sequences with
those of irrelevant proteins (e.g., lamin C) abolished the
interaction (Table I), further confirming the specificity of 
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the interaction. We also found that MIBP interacts with
the 
 
b
 
1A cytoplasmic domain (Table I). Northern blot
analysis of human tissues revealed that MIBP mRNA is
predominantly expressed in skeletal and cardiac muscle
(Fig. 1 B). No expression was detected in brain, placenta,
lung, liver, kidney, or pancreas (Fig. 1 B).
 
MIBP Is Predominantly Expressed in Skeletal Muscle
 
To facilitate studies on MIBP, we generated a monoclonal
anti-MIBP antibody (5B4.7) using His–MIBP fusion pro-
tein as an antigen. mAb 5B4.7 recognizes both His–MIBP
(Fig. 2 A, lane 3) and MBP–MIBP (Fig. 2 A, lane 2), but
not MBP (Fig. 2 A, lane 1) or an irrelevant His-tagged
protein (Fig. 2 A, lane 8). Moreover, analyses of mAb
5B4.7 with a series of MIBP deletion mutants revealed
 
that it recognizes an epitope located within the NH
 
2
 
-termi-
nal region (residues 1–109) of MIBP (Fig. 2 A, lanes 4–7).
To test whether mAb 5B4.7 recognizes endogenous MIBP
expressed by mammalian cells, we probed mouse C2C12
myoblast lysates. The results showed that it recognizes a
single protein band with an apparent molecular mass of
 
z
 
19 kD, which is similar to the predicated mass of MIBP
(Fig. 2 B, lane 2). Furthermore, binding of the antibody to
endogenous 19-kD protein was completely inhibited by an
excess of MBP–MIBP (Fig. 2 B, lanes 3–6), but not of
MBP (Fig. 2 B, lane 7). We conclude that mAb 5B4.7 spe-
cifically recognizes mammalian MIBP as well as recombi-
nant MIBP proteins.
Next, we analyzed the expression of MIBP protein in
different human tissues using the monoclonal anti-MIBP
antibody. Consistent with the results from Northern blot-
ting (Fig. 1 B), MIBP protein was detected in skeletal mus-
cle and heart, but not in other tissues (Fig. 2 C). However,
although abundant MIBP mRNA was detected in the
heart (Fig. 1 B), the level of MIBP protein in the heart was
significantly lower than in skeletal muscle (Fig. 2 C), sug-
gesting that the tissue-specific expression of MIBP may be
controlled at the translational as well as the transcriptional
level.
 
MIBP Binds to 
 
b
 
1 Integrins In Vitro and In Vivo
 
To test whether MIBP can directly bind to the 
 
b
 
1 integrin
cytoplasmic domain, we expressed and purified a GST fu-
sion protein containing the 
 
b
 
1D cytoplasmic domain.
GST–
 
b
 
1D (Fig. 3 A, lane 2), but not GST (Fig. 3 A, lane
1), readily interacted with the purified recombinant His-
tagged MIBP, indicating that the two proteins can directly
interact with each other in the absence of other proteins.
In addition, mammalian MIBP protein expressed by the
C2C12 myoblasts was coprecipitated with GST–b1D fu-
sion protein (Fig. 3 B, lane 3) but not GST (Fig. 3 B, lane
2). Thus, both mammalian and recombinant MIBP pro-
teins interact with the b1 integrin cytoplasmic domain in
vitro. To test whether MIBP associates with b1 integrins in
vivo, we expressed a FLAG-tagged MIBP in mammalian
cells (Fig. 3 D, lane 1). Coimmunoprecipitation experi-
ments with a monoclonal anti-FLAG antibody showed
that the b1 integrins (Fig. 3 C, lane 2) were specifically co-
precipitated with FLAG-MIBP (Fig. 3 D, lane 2) from the
lysate of the FLAG-MIBP transfectants, but not from that
Figure 1. Primary structure and tissue distribution of MIBP. (A)
Nucleotide and deduced amino acid sequences of human MIBP.
The amino acid sequence is shown below the nucleotide se-
quence, and the asterisk indicates the stop codon (sequence data
available from EMBL/GenBank/DDBJ under accession no. AF
190819). (B) Northern blot of MIBP mRNA in human tissues. 2 mg
of polyA1 RNA from human tissues were hybridized with a
cDNA probe specific for MIBP.
Table I. Interactions of MIBP with Cytoplasmic Domains of b1 
Integrins in Yeast Two-Hybrid Binding Assay
pB42AD construct pLexA construct
Reporter gene
LEU2 LacZ
pB42AD-MIBP pLexA-b1D 11
pB42AD-MIBP pLexA-b1A 11
pB42AD-MIBP pLexA 22
pB42AD-MIBP pLexA-lamin C 22
pB42AD pLexA-b1D 22
pB42AD pLexA-b1A 22
Interactions between proteins encoded by the pLexA and pB42AD constructs were de-
termined by the activation of the reporter genes (LEU2 and LacZ). pLexA-b1D con-
tains residues 749–801 of the b1D integrin cytoplasmic domain. pLexA-b1A contains
residues 749–798 of the b1A integrin cytoplasmic domain.The Journal of Cell Biology, Volume 147, 1999 1394
of the control transfectants (Fig. 3 C, lane 5). In additional
control experiments, no b1 integrins were precipitated
from the FLAG-MIBP lysates with a control mouse IgG
(Fig. 3, C and D, lane 3). Thus, MIBP forms a complex
with the b1 integrins in mammalian cells as well as in vitro.
The Membrane-proximal Region of the b1 Integrin 
Cytoplasmic Domains Mediates the Interaction
with MIBP
The cytoplasmic domains of b1D and b1A share a com-
mon membrane-proximal region. Since MIBP binds to
both  b1D and b1A cytoplasmic domains (Table I), it most
likely recognizes a site located within this region. To test
this, we generated a series of b1D/b1A mutants and ana-
lyzed their ability to interact with MIBP in yeast two-
hybrid binding assays. The results showed that MIBP spe-
cifically interacts with the membrane-proximal region of the
b1D or b1A cytoplasmic domain (Table II).
The Expression of MIBP Is Downregulated during 
Myoblast Differentiation
To begin to investigate the role of MIBP in myogenic dif-
ferentiation, we analyzed MIBP expression during myo-
genic differentiation using the mouse C2C12 myoblast line
as a model system. The results showed that abundant
MIBP protein is expressed before terminal differentiation
of C2C12 myoblasts (Fig. 4 A, lane 1). Myogenic differen-
tiation was induced by switching the culture medium to
DME containing 2% horse serum. Myotubes were ob-
served within the first 2 d of induction, and .80% of the
cells were fused into multinucleated myotubes on day 4.
The MIBP expression level was decreased upon induction
of myogenic differentiation (Fig. 4 A, lanes 2–8). Less than
10% of MIBP was expressed 4 d after the induction of dif-
ferentiation (Fig. 4 A, compare lanes 2 and 6), and the ex-
pression of MIBP was further decreased beyond detection
after day 5. In control experiments, the same membrane
was stripped and reprobed with an anti–b1 integrin anti-
body (MC231, which recognizes both b1A and b1D inte-
grins). The b1 integrins (b1A and/or b1D) were detected
at all stages of C2C12 differentiation (Fig. 4 B, lanes 1–8).
Figure 2. MIBP is predominantly expressed in skeletal muscle.
(A) Immunoblot with mAb 5B4.7. Each lane was loaded 10 ng of
recombinant proteins. Lane 1, MBP; lane 2, MBP–MIBP; lane 3,
His–MIBP; lanes 4–7, His fusion proteins containing partial
MIBP sequences as indicated in the figure; and lane 8, His fusion
protein containing an irrelevant protein Nck2. (B) Immunoblot
showing mAb 5B4.7 specifically recognizes mammalian MIBP.
Equal amounts of C2C12 cell extracts (5 mg/lane) were probed
with 3.3 nM irrelevant control mouse IgG (lane 1), 3.3 nM mAb
5B4.7 (lane 2), 3.3 nM mAb 5B4.7 preincubated with 1.65 nM
(lane 3), 3.3 nM (lane 4), 16.5 nM (lane 5), or 33 nM (lane 6)
MBP–MIBP, or 3.3 nM mAb 5B4.7 preincubated 33 nM MBP
(lane 7). Note that binding of mAb 5B4.7 to mammalian MIBP
was blocked by an excess amount of MBP–MIBP (lanes 5 and 6)
but not of MBP (lane 7). (C) MIBP is predominantly expressed
in skeletal muscle. Equal amounts (15 mg/lane) of human fetal
tissues were analyzed by immunoblotting with mAb 5B4.7.
Table II. MIBP Binds to the Membrane-proximal Region of the 
b1 Integrin Cytoplasmic Domain
b1D integrin cytoplasmic
domain deletion mutants b1D integrin sequence
MIBP
binding
Int b1D (749–801) LIWKLLMIIHDRREFAKFEKEKMNAKW 1
DTQENPIYKSPINNFKNPNYGRKAGL
DBDMT1 (749–795) LIWKLLMIIHDRREFAKFEKEKMNAKW 1
DTQENPIYKSPINNFKNPNY
DBDMT2 (749–785) LIWKLLMIIHDRREFAKFEKEKMNAKW 1
DTQENPIYKS
DBDMT3 (749–777) LIWKLLMIIHDRREFAKFEKEKMNAKW 1
DT
DBDMT4 (773–801) ------------------------AKW 2
DTQENPIYKSPINNFKNPNYGRKAGL
Interactions between proteins encoded by the pLexA and pB42AD constructs were de-
termined by the activation of the reporter genes LEU2 and LacZ.Li et al. Muscle Integrin Binding Protein 1395
Overexpression of MIBP in Myoblasts Inhibits 
Myogenic Differentiation
The striking downregulation of MIBP during myogenic
differentiation suggests that a higher MIBP expression
level may prevent myoblasts from undergoing terminal
differentiation. To test this, we overexpressed FLAG-
tagged MIBP in C2C12 myoblasts. The expression of
FLAG-tagged MIBP in the FLAG-MIBP transfectants,
but not C2C12 cells transfected with a vector lacking the
MIBP sequence, was confirmed by immunoblotting with
an anti-FLAG antibody (Fig. 5 A, lanes 1 and 2) and the
anti-MIBP antibody 5B4.7 (Fig. 5 A, lanes 3 and 4). Two
independently isolated C2C12 clones (E3.11 and D9.8)
that express FLAG-MIBP at a level comparable to that
of endogenous MIBP in the proliferating myoblasts (Fig.
5 B) were selected for further analysis. As expected,
myogenin (a biochemical marker for myogenic differenti-
ation; Andrés and Walsh, 1996) (Fig. 5 C) and abundant
multinucleated myotubes (Fig. 5 E) were detected in
both the parental C2C12 cells and the vector control
transfectants after induction of myoblast differentiation.
In contrast, no multinucleated myotubes were detected
in E3.11 and D9.8 cells overexpressing FLAG-MIBP un-
der identical experimental conditions (Fig. 5 E). Similar
results were obtained with all other FLAG-MIBP–over-
expressing C2C12 clones that were analyzed (Fig. 5 E).
Consistent with the suppression of myotube formation,
no myogenin was detected in the cells overexpressing
FLAG-MIBP (Fig. 5 C, lanes 6 and 8). The expression of
FLAG-MIBP in the FLAG-MIBP transfectants but not
the parental C2C12 or the vector control transfectants,
before and after the induction of myoblast differentiation
was confirmed by immunoblotting with an anti-FLAG
antibody (Fig. 5 D). We conclude from these experi-
Figure 3. MIBP interacts
with  b1 integrins in vitro and
in vivo. (A) MIBP directly
interacts with the b1 integrin
cytoplasmic domain in vitro.
His–MIBP was incubated
with glutathione–Sepharose
beads, to which GST (lane 1)
or GST–b1D fusion protein
was bound (lane 2). His–
MIBP bound to GST–b1D
was detected by immuno-
blotting with anti-MIBP anti-
body 5B4.7. (B) Coprecipita-
tion of mammalian MIBP
with GST–b1D fusion pro-
tein. C2C12 lysates were in-
cubated with beads coupled
to GST (lane 2) or GST–b1D
(lane 3). MIBP bound to the
GST fusion protein was de-
tected by immunoblotting
with anti-MIBP antibody
5B4.7. Lane 1 was loaded
with 5 mg C2C12 lysate. (C
and D) b1 integrins associate
with MIBP in mammalian
cells. Anti-FLAG (lanes 2
and 5) or control mouse IgG
(lane 3) immunoprecipitates
were prepared using lysates
of FLAG-MIBP transfec-
tants (lanes 2 and 3) or
FLAG control transfectants
(lane 5) as described in Ma-
terials and Methods. Lanes 1
and 4 were loaded with 3 mg
of the FLAG-MIBP and
FLAG control lysates, re-
spectively. b1 integrins (C)
and FLAG-MIBP (D) were
detected by immunoblotting
with anti–b1 integrin anti-
body MC231 and anti-FLAG
antibody M5, respectively.The Journal of Cell Biology, Volume 147, 1999 1396
ments that overexpression of FLAG-tagged MIBP in
C2C12 myoblasts suppresses terminal myogenic differen-
tiation.
Discussion
In this study, we have identified and cloned a novel muscle
b1 integrin binding protein, MIBP, and provided strong
Figure 4. Downregulation of MIBP expression during myogene-
sis. (A) Mouse C2C12 cells were induced to differentiate by
switching the medium to DME containing 2% horse serum at day
0. Cells were harvested from 1 d before induction to 6 d after in-
duction. Equal amounts (5 mg) of the cell extracts were loaded
onto each lane. MIBP was detected by immunoblotting with
mAb 5B4.7. (B) Expression of b1 integrins during C2C12 differ-
entiation. The membrane in A was stripped and reprobed with
antibody MC231 that recognizes both b1A and b1D integrins.
Figure 5. Overexpression of FLAG-MIBP inhibits C2C12 myo-
genesis. (A) Lysates (5 mg/lane) of the FLAG-MIBP (lanes 2 and
4) and the vector only control (lanes 1 and 3) transfectants were
immunoblotted with anti-FLAG antibody M5 (lanes 1 and 2) or
anti-MIBP antibody 5B4.7 (lanes 3 and 4). (B) Lysates (5 mg/
lane) of parental C2C12 cells (lane 1), the vector-only control
(lane 2), FLAG-MIBP–expressing E3.11 (lane 3), and D9.8 (lane
4) clones were immunoblotted with anti-MIBP antibody 5B4.7.
(C and D) Cells were harvested immediately before induction of
differentiation or 4 d after the induction as indicated in the fig-
ure. The expression of myogenin (C) and FLAG-MIBP (D) was
analyzed by immunoblotting with monoclonal antimyogenin an-
tibody F5D and anti-FLAG antibody M5, respectively. Each lane
was loaded with 10 mg of the cell extracts. E shows the morphol-
ogy of proliferating myoblasts (panels a, c, e, g, i, k, and m) and
myoblasts that were induced to differentiate for 4 d (panels b, d,
f, h, j, l, and n). Panels a and b are parental C2C12 cells, c and d
are control-transfected cells, e–n are FLAG-MIBP transfected
clones E3.11 (panels e and f), D9.8 (panels g and h), B3 (panels i
and j), C4 (panels k and l), and D4 (panels m and n). Bar, 200 mm.Li et al. Muscle Integrin Binding Protein 1397
evidence for an important role of MIBP in the regulation
of terminal myogenesis. Using C2C12 myogenic cells as a
model system, we show that MIBP is abundantly ex-
pressed in proliferating myogenic cells. The expression
level of MIBP decreases upon induction of terminal myo-
genic differentiation, and becomes undetectable after the
majority of the myoblasts have fused to form multinucle-
ated myotubes. This striking downregulation of MIBP sug-
gests that the amount of MIBP may be a crucial element in
the decision-making process of fusion versus proliferation
during myogenic differentiation. In support of this, over-
expression of an epitope-tagged MIBP under a promoter
that is not subject to regulation in muscle cells resulted in a
complete suppression of the terminal differentiation of
C2C12 cells.
MIBP is shown to bind to the b1 integrin cytoplasmic
domain, which is known to play a key role in controlling
myoblast proliferation and differentiation (Sastry et al.,
1999). In addition to suppression of myogenic differentia-
tion, our preliminary results indicate that after switching
to differentiation medium, expression of FLAG-MIBP in
C2C12 myoblasts enhances cell proliferation (Li, J., R.
Mayne, and C. Wu, unpublished observations). Taken to-
gether, our results suggest that MIBP most likely functions
in the regulation of myogenesis via its interaction with the
b1 integrin cytoplasmic domain. In this regard, it is partic-
ularly interesting to note that the MIBP-binding site is lo-
cated within the membrane-proximal region of the b1 in-
tegrin cytoplasmic domain, a region likely to play an
important role in integrin activation (Hughes et al., 1996).
It has been shown that the ligand binding affinity of a5b1
integrin in myoblasts is downregulated during myogenesis
(Boettiger et al., 1995). Moreover, this inactivation of
a5b1 integrin is functionally important to myogenesis
(Boettiger et al., 1995) and could potentially contribute to
the matrix switch (from a fibronectin-rich matrix to a lami-
nin-rich matrix) that accompanies myogenic differentia-
tion (Gullberg et al., 1998). Thus, one mechanism whereby
MIBP potentially functions is by regulating integrin acti-
vation, and consequently, matrix deposition and cell adhe-
sion. In addition, MIBP could modulate signal transduc-
tion from integrins to other downstream targets such as
focal adhesion kinase and paxillin (Sastry et al., 1999), and
thereby influence the decision of myoblasts to fuse and un-
dergo terminal differentiation.
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